Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences

Table 4 Deterministic Results

	Apixaban	LMWH/VKA/Placebo	Difference	Apixaban	LMWH/VKA	Difference
Number of events (total population)
Recurrent VTE and VTE-related death	514	577	−62	514	508	6
VTE-related death	63	71	−8	63	63	0
Recurrent PE	130	146	−16	130	129	1
Recurrent DVT	321	359	−39	321	316	5
Major bleeds	123	136	−13	123	149	−26
CRNM bleed	603	631	−28	603	714	−111
Treatment discontinuation due to adverse events	109	58	51	109	139	−30
Costs
Anticoagulant costs	£1121	£98	£1023	£1121	£98	£1023
Monitoring and administration costs^a	£63	£261	-£200	£63	£446	-£385
Event-related costs	£4069	£4214	-£145	£4069	£4170	-£101
QALYs	8.488	8.386	0.101	8.488	8.425	0.063
Life-years	10.421	10.311	0.110	10.421	10.375	0.046
Cost per QALY gained		£6692			£8528

^aMonitoring costs observed in the apixaban arm were attributed to the use of LMWH/VKA in patients who had a recurrent VTE event beyond the specified apixaban treatment period

ISSN: 1472-6963